Getinge B, SE0000202624

Getinge stock wins support as analysts lift price targets

Published on 11/11/2026 at 03:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Getinge stock has won broader analyst support after the October report. Handelsbanken raised its target and switched its rating to Buy.

Analysts raise Getinge targets

Eleven research houses lifted their Getinge targets after the October 21 interim report.
Seven of eleven included analysts rate the stock Buy, while three rate it Hold and one rates it Sell.
Getinge kept its 2026 outlook for 3% to 5% organic sales growth, adjusted for the Surgical Perfusion phase-out.

Getinge B, SE0000202624, Illustration mit AI erstellt.

Getinge stock has attracted broader analyst support after the company's interim report for the third quarter on October 21, 2026. In a BioStock consensus analysis published on October 29, all eleven research houses that updated their targets after the report had raised them.

Handelsbanken upgraded Getinge from Hold to Buy on October 22 and lifted its target to SEK 310 from SEK 265. The target panel ranged from SEK 193 to SEK 320, with seven of eleven included houses recommending Buy, three Hold and one Sell.

Margins and cash flow improve

Getinge reported third-quarter net sales of SEK 8.446 billion, up from SEK 8.226 billion a year earlier, according to the BioStock analysis. Adjusted EBITA rose to SEK 1.278 billion from SEK 1.079 billion, lifting the margin to 15.1% from 13.1%.

Free cash flow increased to SEK 1.302 billion from SEK 793 million. The figures included SEK 45 million from tariff refunds and about SEK 36 million from currency effects, so investors must distinguish operating improvement from these reported influences.

Getinge kept its 2026 outlook for 3% to 5% organic sales growth, adjusted for the phase-out of Surgical Perfusion. The next market focus is therefore likely to remain on margin execution, cash generation and delivery against that outlook.

Getinge's medtech business

Getinge develops medical technology and integrated solutions aimed at improving patient outcomes. Its main business areas are Acute Care Therapies, Life Science and Surgical Workflows, serving healthcare customers internationally from its headquarters in Gothenburg, Sweden.

The company has a global medical technology presence, with around 12,000 employees in 40 countries, according to Getinge. Its specialization spans operating-room equipment, sterilization, life-science solutions and acute-care products.